Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment. 2014

R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
Medical University of Silesia. rbuldak@sum.edu.pl.

The aim of the study was to assess the expression and subcellular localization of visfatin in HCT-116 colorectal carcinoma cells after cytokinesis failure using Cytochalasin B (CytB) and the mechanism of apoptosis of cells after CytB. We observed translocation of visfatin's antigen in cytB treated colorectal carcinoma HCT-116 cells from cytosol to nucleus. Statistical and morphometric analysis revealed significantly higher area-related numerical density visfatin-bound nano-golds in the nuclei of cytB-treated HCT-116 cells compared to cytosol. Reverse relation to visfatin subcellular localization was observed in un-treated HCT-116 cells. The total amount of visfatin protein and visfatin mRNA level in HCT-116 cells was also decreased after CytB treatment. Additionally, CytB significantly decreased cell survival, increased levels of G2/M fractions, induced bi-nuclei formation as well as increased reactive oxygen species (ROS) level in HCT-116 cells. CytB treatment showed cytotoxic effect that stem from oxidative stress and is connected with the changes in the cytoplasmic/nuclear amount of visfatin in HCT-116 cells.

UI MeSH Term Description Entries
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003571 Cytochalasin B A cytotoxic member of the CYTOCHALASINS. Phomin
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049329 Nanostructures Materials which have structured components with at least one dimension in the range of 1 to 100 nanometers. These include NANOCOMPOSITES; NANOPARTICLES; NANOTUBES; and NANOWIRES. Nanomaterials,Nanostructured Materials,Material, Nanostructured,Materials, Nanostructured,Nanomaterial,Nanostructure,Nanostructured Material
D054409 Nicotinamide Phosphoribosyltransferase An enzyme that catalyzes the formation of nicotinamide mononucleotide (NMN) from nicotinamide and 5-phosphoribosyl-1-pyrophosphate, the rate-limiting step in the biosynthesis of the NAD coenzyme. It is also known as a growth factor for early B-LYMPHOCYTES, or an ADIPOKINE with insulin-mimetic effects (visfatin). Pre-B-Cell Colony-Enhancing Factor,Visfatin,NAMPT Protein,NAmPRTase,NMN Pyrophosphorylase,Colony-Enhancing Factor, Pre-B-Cell,Phosphoribosyltransferase, Nicotinamide,Pre B Cell Colony Enhancing Factor

Related Publications

R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
January 2013, International journal of molecular and cellular medicine,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
June 2021, Analytical biochemistry,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
December 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
January 2022, Saudi journal of biological sciences,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
August 2015, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
January 2017, Oncotarget,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
August 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
September 2022, BMC molecular and cell biology,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
January 2020, Journal of oncology,
R J Bułdak, and M Skonieczna, and Ł Bułdak, and N Matysiak, and Ł Mielańczyk, and G Wyrobiec, and M Kukla, and M Michalski, and K Żwirska-Korczala
June 2019, European journal of pharmacology,
Copied contents to your clipboard!